Zasocitinib not checked

Takeda · TAK-279 · NDI-034858

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
13 active
26 in total · 13 in the EU
Targets
 

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
Tested for
Psoriatic Arthritis (4 trials), Crohn's Disease (3 trials), Plaque Psoriasis (2 trials), Ulcerative Colitis (2 trials), Palmoplantar Psoriasis, Hidradenitis Suppurativa, Nonsegmental Vitiligo
Main trialPhase 3
“Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.”In the company’s words, NCT06671483 on ClinicalTrials.gov
Other names
TAK-279 · NDI-034858

Other drugs for Psoriatic Arthritis

All 29 drugs for Psoriatic Arthritis

Coming up12

Changes2

Last 90 days

Trials26

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 18 May 2027 A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Phase 3Active, not recruiting 18 May 2027 A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Phase 3Not yet recruiting 30 May 2027 A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
Phase 3Active, not recruiting 5 Aug 2029 A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Phase 3Recruiting 18 Dec 2029 Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Phase 3Not yet recruiting 18 Apr 2030 A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Phase 3Recruiting 3 Jul 2034 A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Phase 2Active, not recruiting 14 Jul 2026 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2Active, not recruiting 5 Feb 2027 A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Phase 2Recruiting 17 Feb 2027 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Phase 2Active, not recruiting 26 Mar 2027 A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Phase 2Recruiting 30 Mar 2028 A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
Phase 2Recruiting 30 Dec 2029 A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Phase 3Completed 6 Dec 2024 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
Phase 3Completed 22 Jan 2025 A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Phase 3Completed 17 Oct 2025 A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Phase 3Completed 22 Apr 2026 A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Phase 2Completed 19 Aug 2022 Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis
Phase 2Completed 4 May 2023 A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
Phase 1Completed 18 Dec 2023 A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
Phase 1Completed 15 Apr 2024 A Study of TAK-279 in Adults With or Without Liver Damage
Phase 1Completed 3 May 2024 A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults
Phase 1Completed 22 May 2024 A Study of TAK-279 in Adults With or Without Kidney Problems
Phase 1Completed 25 Jun 2024 A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements
Phase 1Completed 23 Jul 2024 A Study of TAK-279 in Healthy Chinese Adults
Phase 1Completed 11 Mar 2025 A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Zasocitinib

Following is part of Solo: you see every change to Zasocitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in